Phase I Study of Cisplatin And ZD1839 (IRESSA) [gefitinib] in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck.

Trial Profile

Phase I Study of Cisplatin And ZD1839 (IRESSA) [gefitinib] in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Cisplatin; Gefitinib
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 May 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
    • 23 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top